The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for the following active substances / combinations of active substances in the context of a so-called open house procedure:

- enoxaparin (B01AB05),

- Fulvestrant (L02BA03),

- fusidic acid (D06AX01),

- lipegfilgrastim (L03AA14),

- Macrogol combinations (A06AD65),

- octreotide (H01CB02),

- pyridostigmine (N07AA02),

- Tiotropium & Olodaterol (R03AL06).

All suitable and interested pharmaceutical companies or associations of pharmaceutical companies are offered the conclusion of a discount agreement in accordance with Section 130a (8) SGB V for the above-mentioned active ingredients / active ingredient combinations, subject to standardized contractual conditions and a standardized access procedure.

The earliest contract start is March 1st, 2021. Based on this, the contract term is a maximum of 24 months.

Providing uniform contractual terms and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the conclusion of a discount contract in accordance with Section 130a (8) SGB V for the active substances / combinations of active substances mentioned.

Dortmund The earliest contract start is March 1st, 2021. Based on this, the contract term is a maximum of 24 months.